Zusammenfassung
Als Mukus wird das tracheobronchiale Sekret bezeichnet, das von sekretorischen Zellen (Becherzellen, Clarazellen) und Drüsen (submuköse Drüsen) gebildet wird und seröse (serumvergleichbare) und muköse (schleimige) Anteile besitzt
Chapter PDF
Similar content being viewed by others
Literatur
Liteatur zu 4.1
Weibel E (1963) Morphometry of the human lung. Springer, Berlin Heidelberg New York
App EM, King M, Helfesrieder R, Köhler D, Matthys H (1990) Acute and long term amiloride inhalation in cystic fibrosis lung disease. Am Rev Respir Dis 141:605–612
King M, Gilboa A, Meyer FA, Silberberg A (1974) On the transport of mucus and its rheological simulants in ciliated systems. Am Rev Respir Dis 110:740–745
Man SFP, Adams GK III, Proctor DF (1979) Effects of temperature, relative humidity, and mode of breathing on canine airway secretions. J Appl Physiol 46:205–210
Williams R, Rankin N, Smith T, Galler D, Seakins P (1996) Relationship between the humidity and temperature of inspired gas and the function of the airway mucosa. Crit Care Med 24:1920–1929
Wanner A (1977) Clinical aspects of mucociliary transport. Am Rev Respir Dis 116:73–125
Giordano AM, Holsclaw D, Litt M (1978) Mucus rheology and mucociliary clearance: Normal physiological state. Am Rev Respir Dis 118:245–254
Iravani J, Melville GN (1975) Wirkung von Pharmaka und Milieuänderungen auf die Flimmertätigkeit der Atemwege. Respiration 32:157–164
Lucas AM, Douglas LC (1934) Principles underlying ciliary activity in the respiratory tract. II. A comparison of nasal clearance in man, monkey and other mammals. Arch Otolaryngol 20:518–541
Schürch S, Gehr P, Im Hof V, Geiser M, Green F (1990) Surfactant displaces particles towards the epithelium in airways and alveoli. Respir Physiol 80:17–32
Godleski JJ, Hastings CL, Katler M, Sweeney TD (1991) Preservation of the relationship of airway mucus and epithelium by slam freezing. Proceedings of the 49th Annual Meeting of the Electron Microscopy Society of America (EMSA), San Francisco Press, pp 72–73
Asmundsson T, Kilburn KH (1970) Mucociliary clearance rates of various levels in dog lungs. Am Rev Respir Dis 102: 388–397
Leith DE (1977) Cough. In: Brain J, Proctor DF, Reid LM. Respiratory defence mechanism, part 2, New York, p545
Matthews LW, Spector S, Lemm J, Potter J (1963) Studies of pulmonary secretions. I. The overall composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am Rev Respir Dis 88:199–204
Welsh MJ, Ostedgaard LS (1998) Cystic fibrosis problem probed by proteolysis. Nat Struct Biol 5:167–169
Knowles MR, Robinson JM, Wood RE, Pue CA, Mentz WM, Wager GC, Gatzy JT, Boucher, RC (1997) Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 100:2588–2595
Boat TF, Cheng PW, Iyer RN, Carlson DM, Polony I (1976) Human respiratory tract secretions: mucous glycoproteins of nonpurulent tracheobronchial secretions, and sputum of patients with bronchitis and cystic fibrosis. Arch Biochem Biophys 177: 95–104
Puchelle E, de Bentzmann S, Zahm JM (1995) Physical and functional properties of airway secretions in cystic fibrosis — therapeutic approaches. Respiration 62:2–12
Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP (1994) Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263:969–971
App EM, Wunderlich MO, Lohse P, King M, Matthys H (1999) Oszillierende Physiotherapie bei Bronchialerkrankungen — rheologischer und antientzündlicher Effekt. Pneumologie 53:348–359
King M, Brock G, Lundell C (1985) Clearance of mucus by simulated cough. J Appl Physiol 58:1776–1782
King M (1987) Role of mucus viscoelasticity in cough clearance. Biorheology 24:589–597
App EM (1994) Sekretanalyse und Clearance. Atemw Lungenkrankh 20:363–371
Zahm JM, King M, Duvivier C, Pierrot D, Girod S, Puchelle E (1991) Role of simulated repetitive coughing in mucus clearance. Eur Respir J 4:311–315
Newhouse MT, Rossman CM, Dolovich J, Dolovich MB, Wilson WM (1976) Impairment of mucociliary transport in cystic fibrosis. Mod Probl Paediat 19:190–198
Rutland J, Penketh A, Griffin WM, Hodson ME, Batten JC, Cole PJ (1983) Cystic fibrosis serum does not inhibit human ciliary beat frequency. Am Rev Respir Dis 128: 1030–1034
App EM (1996) Vergleichende Mukolytikatherapie. Pneumologie 50:845–853
Köhler D, App EM, Egelseder A, Matthys H (1986) Unterschiede in der mukoziliären und Hustenclearance bei chronischer Bronchitis mit und ohne Mukoviszidose. Atemw Lungenkrankh 12:358–361
Bauernfeind A, Bertele RM, Harms K, Hörl G, Jungwirth R, Petermüller C, Przyklenk B, Weisslein-Pfister C (1987) Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 15: 270–307
Bauernfeind A, Przyklenk B (1997) Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis. Behring Inst, Mitt 98:256–261
Canciani M, Barlocco EG, Mastella G, de Santi MM, Gardi C, Lungarella G (1988) The saccharin method for testing mucociliary function in patients suspected of having primary ciliary dyskinesia. Pediatr Pulmonol 5:210–214
Lieberman J (1968) Measurement of sputum viscosity in a cone-plate viscometer. I. Characteristics of sputum viscosity. Am Rev Respir Dis 97:654–661
Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C (1997) Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med 156:1897–1901
Pavia D, Thomson ML, Clarke SW (1976) Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis 117:199–203
Riedler J, Reade T, Button B, Robertson CF (1996) Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. J Paediatr Child Health 32:48–50
Wills PJ, Hall RL, Chan WM, Cole PJ (1997) Sodium Chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 99:9–13
Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL (1990) Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 87: 9188–9192
Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME (1996) In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 51:119–125
Dasgupgta B, Tomkiewicz RP, De Sanctis GT, Boyd WA, King M (1995) Mucolytic synergism in cystic fibrosis (CF) sputum with combined rhDNase and gelsolin treatment. Am J Respir Crit Care Med 151: A19
DeSanctis GT, Tomkiewicz RP, Rubin BK, Schürch S, King M (1994) Exogenous Surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 7: 1616–1621
App EM, Kieselmann R, Reinhardt D, Lindemann H, Dasgupta B, King M, Brand P (1998) sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy — Flutter vs Autogenic Drainage. Chest 114:171–177
Ordemann J (1993) Randomisierte cross-over Untersuchung zur Wirksamkeit des VRP1 Desitin mittels Messung der mukoziliären und tussiven Clearance. Promotionsarbeit. Zentrum Innere Medizin Abteilung Pneumologie der Albert-Ludwigs-Universität Freiburg im Breisgau
Lindemann H (1992) Zum Stellenwert der Physiotherapie mit dem VRP 1-Desitin („Flutter“). Pneumologie 46: 626–630
Liteatur zu 4.2
1. Agarwal M, King M, Rubin BK und Shukla JB (1989) Mucus transport in a miniaturized simulated cough machine: Effect of constriction and serous layer simulant. Biorheology 26:977–988
2. App EM und King M (1990) Tracheal mucus rheology and potential difference in two day old puppies. Biorheology 27:515–526
App EM, Helfesrieder R, Köhler D, Matthys H (1990) Acute and longterm amiloride inhalation in cystic fibrosis lung disease. Am Rev Respir Dis 141:605–612
App EM, Zayas JG, King M (1993) Rheology of mucus and transepithelial potential difference: small airways vs. trachea. Eur Respir J 6:67–75
App EM (1996) Vergleichende Mukolytikatherapie. Pneumologie 50:845–853
App EM, Tomkiewicz RP, Hahn HL, Engler H, Vergin H, King M (1998) The effect of Tasuldine, a bronchosecretolytic agent, on mucus rheology and clearability and the interaction with acetylcholine in ferrets. Pulm Pharmacol 10:271–276
Barnett B, Dulfano MJ (1970) Sputum viscoelasticity I: New methodology. Am Rev Respir Dis 101:773–776
Boat TF, Cheng PW, Iyer RN, Carlson DM, Polony I (1976) Human respiratory tract secretions: mueous glycoproteins of nonpurulent tracheobronchial secretions, and sputum of patients with bronchitis and cystic fibrosis. Arch Biochem Biophys 177:95–104
Braga PC (1988) Sinusoidal oscillation method. In: Braga PC, Allegra L (eds) Methods in bronchial mucology. Raven Press, New York, pp 63–71
Charman J, Reid L (1972) Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology 9:185–199
Dasgupta B, Tomkiewicz RP, Boyd WA, Brown NE, King M (1995) Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonol 20:78–82
Davis SS, Dippy JE (1969) The rheological properties of sputum. Biorheology 6:11–21
Davis SS (1973) Rheological examination of sputum and saliva and the effect of drugs. In: Gabelnick HL, Litt M (eds) Rheology of biological systems. Charles C Thomas, Springfield,Ill,pp 158–194
Hwang SH, Litt M und Forsman WC (1969) Rheological properties of mucus. Rheol Acta 8:438–448
Jeanneret-Grosjean A, King M, Michoud MC, Lioté H, Amyot R (1988) Sampling technique and rheology of human bronchial mucus. Am Rev Respir Dis 137:707–710
Keal E, Reid L (1970) Méthodes ďétude des modifications de la sécretion bronchique et de sa viscosité. Poumon Coeur 26:52–58
King M, Gilboa A, Meyer FA und Silberberg A (1974) On the transport of mucus and its rheological simulants in ciliated systems. Am Rev Respir Dis 110:740–745
King M (1979) Interrelation between mechanical properties of mucus and mucociliary transport: Effect of pharmacologic interventions. Biorheology 16:57–68
King M, El-Azab J, Phillips DM, Angus GE (1985) Antigen challenge and canine tracheal mucus. Int Arch Allergy Appl Immunol 77:337–342
King M, Brock G, Lundell C (1985) Clearance of mucus by simulated cough. J Appl Physiol 58:1776–1782
King M, Brock G, Lundell C (1985) Clearance of mucus by simulated cough. J Appl Physiol 58:1776–1782
King M (1987) Role of mucus viscoelasticity in cough clearance. Biorheology 24:589–597
King M, Zahm JM, Pierrot D, Vaquez-Girod S, Puchelle E (1989) The role of mucus gel viscosity, spinability, and adhesive properties in clearance by simulated cough. Biorheology 26:737–745
Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher R (1990) A pilot study of aerosolized amiloride for the treatment of cystic fibrosis lung disease. N Engl J Med 332:1189–1194
Litt M, Khan MA, Chakrin LW, Wardell JR, Christian P (1974) The viscoelasticity of fractionated canine tracheal mucus. Biorheology 11:111–117
Lopez-Vidriero MT, Das I, Smith AP, Picot R, Reid L (1977) Bronchial secretion from normal human airways after inhalation of prostaglandin P2a; acetylcholine, histamine, and citric acid. Thorax 32:734–739
Lutz RJ, Litt M, Chakrin LW (1973) Physical-chemical factors in mucus rheology. In: Gabelnick HL, Litt M (eds) Rheology of biological systems. Charles C Thomas, Springfield,Ill,pp 158–194
Majima Y, Hirata K, Takeuchi K, Hattori M, Sakakura Y (1990) Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am Rev Respir Dis 141:79–83
Mariott C, Richards JH (1974) Studies on the variation in the viscosity of bronchial mucus and a technique for reducing such variation. Biorheology 11:129–135
Puchelle E, Zahm JM, Havez R (1973) Données biochimiques et rhéologiques dans ľexpectoration. III Rélation des protéines et mucines bronchiques avec les propriétés. Bull Physiopathol Respir 9:237–256
Puchelle E, Tournier JM, Zahm JM, Sadoul P (1984) Rheology of sputum collected by a simple technique limiting salivary contamination. J Lab Clin Med 103:347–353
Puchelle E, Zahm JM, Duvivier C (1987) Spinability of bronchial mucus: Relationship with viscoelasticity and mucus transport properties. Biorheology 20:239–249
Roussel P, Degand P, Lamblin G, Laine A, Lafitte JJ (1978) Biochemical definition of human tracheobronchial mucus. Lung 154:241–260
Shih CK, Litt M, Khan MA, Wolf DP (1977) Effect of nondialyzable solids concentration and viscoelasticity on ciliary transport of tracheal mucus. Am Rev Respir Dis 115:989–995
Spungin B, Silberberg A (1984) Stimulation of mucus secretion, ciliary activity, and transport in frog palate epithelium. Am J Physiol 247 (Cell Physiol 16):C299–C308
Sturgess J, Palfrey AJ, Reid L (1970) The viscosity of bronchial secretions. Clin Sci 38:145–156
Zahm JM, Puchelle E, Duvivier C, Didelon J (1986) Spinability of respiratory mucus. Validation of a new apparatus: The Filancemeter. Bull Eur Physiopathol Respir 22: 609–613
Liteatur zu 4.3.1
Bals R, Wang X, Wu Z, Freeman T, Bafna V, Zasloff M, Wilson J (1998a) Human beta-defensin 2 is a salt sensitive peptide antibiotic expressed in human lung. J Clin Invest 102:874–880
Bals R, Wang X, Zasloff M, Wilson J (1998b) The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has a broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 95:9541–9546
Beppu Y, Imamura Y, Tashiro M, Towatari T, Ariga H, Kido H (1997) Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with Influenza A and sendai viruses. J Biochem Tokyo 121: 309–316
Britigan B, Hayek M, Doebbeling B, Flick R (1993) Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas infected lungs of patients with cystic fibrosis. Infect Immun 61:5049–5055
Brogan T, Ryley H, Neale L, Yassa J (1975) Soluble proteins of bronchopulmonary secretions from patients with cystic fibrosis, asthma, and bronchitis. Thorax 30:72–79
Crouch E (1998) Collectins and pulmonary host defense. Am J Resp Cell Mol Biol 19:177–210
Fisher A, Dodia C, Chander A (1994) Inhibition of lung cal-cium-independent phospholipase A2 by surfactant protein A. Am J Physiol 267:L335–L341
Gawels J, Runik J, Pryjma J, Zebrak J, Haluszka J, Rudnik I, Majewska-Zalewska H (1979) Proteins in bronchial secretion of children with chronic pulmonary diseases. Scand J Resp Dis 60:63–68
Goss K, Kumar A, Snyder J (1998) SP-A2 gene expression in human fetal lung airways. Am J Respir Cell Mol Biol 19: 613–621
Griese M, Pudenz P, Gebhard W (1998) Inhibitors of Ekstase in Airway Lavage Samples from Ventilated Preterm Human Neonates. Am J Respir Crit Care Med 158:256–262
Griese M (1999) Pulmonary surfactant in health and lung diseases: State of the art. Eur Respir J 13:1455–1476
Griese M, Birrer P, Demirsoy A (1997a) Pulmonary Surfactant in cystic fibrosis. Eur Respir J 10:1983–1988
Griese M, Duroux A, Schams A, Lenz AG, Kleinasser N (1997b) Tracheobronchial surface active material in cystic fibrosis. Eur J Med Res 2:114–120
Griese M, Schredl M, Hochstrasser K, Gebhard W (1997c) Cellular association of antiproteases in lavages from ventilated preterm human neonates. Am J Respir Crit Care Med 155:2064–2071
Heczko P, Gutkowski P, Pulverer G (1977) Immunoglobulins A and G and lysozyme in the bronchial secretions of children with acute respiratory tract infections. Z Erkrank AtemwOrg 147:168–170
Hiemstra PS, Maasen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH (1996) Antibacterial activity of antileukoprotease. Infect Immun 64:4520–4524
Hughes W, Koblin B, Rosenstein B (1982) Lysozyme activity in cystic fibrosis. Pediatr Res 16:874–876
Hull J, South M, Phelan P, Grimwood K (1997) Surfactant composition in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 156:161–165
Jacquot J, Tournier J, Carmona T, Puchelle E, Chazalette J, Sadoul P (1983) Proteines des secretions bronchiques dans la mucoviscdose, Role de línfection. Bull Eur Physiopathol Respir 19:453–458
Jin F, Nathan C, Radzioch D, Ding A (1998) Lipopoly-saccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun 66:2447–2452
Jin F, Nathan C, Radzioch D, Ding A (1997) Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolisaccharide. Cell 88:417–426
Kim D, Fukuda T, Thompson B, Cockrill B, Haies C, von Bonventre J (1995) Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult resiratory distress. Am J Physiol 269:L109–L118
Kronborg G, Shand G, Fomsgaard A, Hoiby N (1992) Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS 100: 175–180
Mason R, Greene K, Voelker DR (1998) Surfactant protein A and Surfactant protein D in health and disease. Am J Physiol 275:L1–L13
McElvaney N, Nakamura H, Birrer P, Hebert C, Wong W, Alphonso M, Baker J, Catalano M, Crystal RG (1992) Modulation of airway inflammation in cystic fibrosis. J Clin Invest 90:1296–1301
McNeely T, Shugars D, Rosendahl M, Tucker C, Eisenberg S, Wahl S (1997) Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease in hibitor occurs prior to viral reverse transcription. Blood 90: 1141–1149
Postle AD, Mander A, Reid KM, Wang JY, Wright S, Moustaki M, Warner J (1999) Deficient hydrophilic lung Surfactant proteins A und D with normal Surfactant phospholipid molecular spiecies in cystic fibrosis. Am J Respir Cell Mol Biol 20:90–98
Pryjma J, Herman T, Zebrak J, Gawels J, Herman S, Scislicki A (1985) Studies on bronchial secretion. The influence of inflammatory response and bacterial infection. Ann Allergy 54:60–64
Qu X-D, Lehrer R (1998) Secretory phospholipase A2 is the principal bactericide for staphylococci and other grampositive bacteria in human tears. Infect Immun 66: 2791–2797
Rose F, Bailey K, Keyte J, Chan W, Greenwood D, Mahida Y (1998) Potential role of epithelial cell-derived histone Hl proteins in innate antimicrobial defense in the human gastrointestinal tract. Infect Immun 66:3255–3263
Saitoh H, Okayama H, Shimura S, Fushimi T, Masuda T, Shirato K (1998) Surfactant protein A2 gene expression by human airway submucosal gland cells. Am J Respir Cell Mol Biol 19:202–209
Samet J, Madden M, Fonteh A (1996) Characterization of a secretory phospholipase A2 in human bronchoalveolar lavage fluid. Exp Lung Res 22:299–315
Stelzner A, Groh A, Lehnert U (1988) Vergleichende Bronchialsekretuntersuchungen bei Kindern mit chronischen, nichttuberkulösen Lungenerkrankungen. Allerg Immunol 34:99–108
Stromatt S (1993) Secretory leukocyte protease inhibitor in cystic fibrosis. Agents Act 42:103–110
Thompson A, Bohling T, Payvandi F, Rennard S (1990) Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis. J Lab Clin Med 115:148–158
Tomee J, Koeter G, Hiemstra P, Kaufman H (1998) Secretory leukocyte protease inhibitor: a native antimicrobial protein presenting a new therapeutic Option? Thorax 53: 114–116
Tomita M, Takase M, Wakabayashi H, Bellamy W (1994) Antimicrobial peptides of lactoferrin. Lactoferrin: Structure and function. Adv Exp Med Br 357:209–218
Wahl S, Worley P, Jin W, McNeely T, Eisenberg S, Fasching C, Orenstein J, Janoff E (1997) Anatomie dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Am J Pathol 150:1275–1284
Wright JR (1997) Immunomodulatory functions of surfactant. Physiol Rev 77:931–961
Xu P, Hashimoto S, Miyazaki H, Asabe K, Shiraishi S, Sueishi K (1998) Morphometric analysis of the immunohistochemical expression of clara cell 10-k-Da protein and surfactant apoproteins A and B in the developing bronchi and bronchioles of human fetuses and neonates. Virchows Arch B 432:17–25
Zebrak J, Herman T, Werys R, Pryjma J, Gawels J (1979) Proteins in bronchial secretion of children with chronic pulmonary diseases. II Relation to bronchoscopic and bronchographic examination. Scand J Respir Dis 60:69–75
Liteatur zu 4.3.2
Bals R, Goldman MJ, Wilson JM (1998) Mouse beta-defen-sin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun 66: 1225–1232
Bals R, Wang X, Wu Z, Freeman T, Banfa V, Zasloff M, Wilson JM (1998) Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 102:874–880
Bals R, Wang X, Zasloff M, Wilson JM (1998) The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 95:9541–9546
Bals R, Weiner D, Wilson J (1999) The innate immune system in cystic fibrosis lung disease. J Clin Invest 103: 303–307
Barra D, Simmaco M, Boman H (1998) Gen-encoded peptide antibiotics and innate immunity. FEBS Lett 430:130–134
Bensch KW, Raida M, Magert H-J, Schulz-Knappe P, Forss-mann W-G (1995) hBD-1: a novel b-defensin from human plasma. FEBS Lett 368:331–335
Boman H (1991) Antibacterial peptides: key components needed in immunity. Cell 65:205–207
Boucher RC (1994) Human airway ion transport (part one). Am J Respir Crit Care Med 150:271–281
Diamond G, Zasloff M, Eck H, Brasseur M, Maloy WL, Bevins CL (1991) Tracheal antimicrobial peptide, a cysteinerich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc Natl Acad Sci USA 88:3952–3956
Fearon D, Locksley R (1996) The instruetive role of innate immunity in the aquired immune response. Science 272: 50–54
Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H, Gudmundsson GH (1997) The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272:15258–15263
Gallo R, Kim K, Bernfield M, Kozak C, Zanetti M, Merluzzi L, Gennaro R (1997) Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 272
Ganz T, Lehrer RI (1995) Defensins. Pharmacol Ther 66: 191–205
Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM (1997) Human beta-defensin-1 is a saltsensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553–560
Grasemann H, Michler E, Wallot M, Ratjen F (1997) Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 24:173–177
Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R (1996) The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 238:325–332
Hancock REW (1997) Peptide antibiotics. Lancet 349: 412–422
Harder J, Bartels J, Christophers E, Schroeder J-M (1997) A peptide antibiotic from human skin. Nature 387:861
Hiemstra P, van Wetering S, Stolk J (1998) Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur Respir J 12:1200–1208
Huttner KM, Kozak CA, Bevins CL (1997) The mouse genome encodes a single homolog of the antimicrobial peptide human beta-defensin 1. FEBS Lett 413:45–49
Imundo L, Barasch J, Prince A, Al-Awqati Q (1995) Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. PNAS USA 92:3019–3023
Jiang C, Finkbeiner W, Widdicombe J, McCray Pj, Miller S (1993) Altered fluid transport across airway epithelium in cystic fibrosis. Science 262:424–427
Kelley T, Drumm M (1998) Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 102:1200–1207
Larrick J, Hirata M, Balint R, Lee J, Zhong J, Wright S (1995) Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 63:1291–1297
Lehrer R, Ganz T, Selsted M (1991) Defensins: endogenous antibiotic peptides of animal cells. Cell: 229–230
Matsui H, Grubb B, Tarran R, Randell S, Gatzy J, Davis C, Boucher R (1999) Evidence for periciliar liquid layer depletion not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell 95:1005–1015
Morrison GM, Davidson DJ, Kilanowski FM, Borthwick DW, Crook K, Maxwell AI, Govan JR, Dorin JR (1998) Mouse beta defensin-1 is a functional homolog of human beta defensin-1. Mamm Genome 9:453–457
Pier GB, Grout M, Saidi TS, Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB (1996) Role of mutant CFTR in hyper-susceptibility of cystic fibrosis patients to lung infections. Science 271:64–67
Popsueva A, Zinovjeva M, Visser J, Zijlmans J, Fibbe W, Belyavsky A (1996) A novel murine cathelin-like protein expressed in bone marrow. FEBS Lett 391:5–8
Quinton P (1990) Cystic fibrosis: a disease in electrolyte transport. FASEB J 4:2709–2717
Schimdt H, Walter U (1994) NO at work. Cell 78:919–925
Singh G, Katyal S (1997) Clara cells and Clara cell 10 kD protein (CC10). Am J Respir Cell Mol Biol 17:141–143
Singh G, Katyal S, Brown W, Kennedy A, Singh U, Wong-Chong M (1990) Clara cell 10 kDa protein (CC10): comparison of structure and function to uteroglobin. Biochem Biophys Acta 1039:348–355
Singh P, Jia H, Wiles K, Hesselberth J, Liu L, Conway B, Greenberg E, Valore E, Welsh M, Ganz T, Tack B, McCray PJ (1998) Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA 95:14961–14966
Smith J, Travis S, Greenberg E, Welsh M (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229–236
Soong L, Ganz T, Ellison A, Caughey G (1997) Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res 46:98–102
Stolzenberg ED, Anderson GM, Ackermann MR, Whitlock RH, Zasloff M (1997) Epithelial antibiotic induced in states of disease. Proc Natl Acad Sci USA 94:8686–8690
Zanetti M, Gennaro R, Romeo D (1995) Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374:1–5
Zasloff M (1991) Antibiotic peptides as mediators of innate immunity. Curr Opin Immunol 4:3–7
Liteatur zu 4.4
Bentzmann D, Pierrot D, Fuchey C, Zahm JM, Morancais JL, Puchelle E (1993) Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus. Eur Respir J 6:1156–1161
Boncuk P, Kaser M, Yu Y, Taeusch HW (1997) Effects of cationic liposome-DNA complexes on pulmonary surfactant function in vitro and in vivo. Lipids 32:247–253
Creery W, Hashmi A, Hutchinson J, Singh R (1997) Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Pediatr Pulmonol 24:370–373
Enhorning C, Duffy LC, Welliver R (1995) Pulmonary surfactant maintains patency of condueting airways in the rat. Am J Respir Crit Care Med 151:554–556
Enhorning G, Holm BA (1993) Disruption of pulmonary surfactants ability to maintain openness of a narrow tube. J Appl Physiol 74:2922–2927
Gehr P, Geiser M, Im Hof V, Schürch S, Waber U, Baumann M (1993) Surfactant and inhaled particles in the condueting airways: structural, stereological and biophysical aspects. Microsc Res Tech 26:423–436
Gehr P, Green F, Geiser M, Im H, Lee M, Schürch S (1996) Airway sufaetant, a primary defense barrier: mechanical and immunological aspects. J Aerosol Med 9:163–181
Gehr P, Schürch S, Berthiaume Y, Im Hof V, Geiser M (1990) Particle retention in airways by surfactant. J Aerosol Med 3:27–43
Gilljam H, Andersson O, Ellin A, Robertson B, Strandvik B (1988) Composition and surface properties of the bronchial lipids in adult patients with cystic fibrosis. Clin Chim Acta 176:29–38
Gilljam H, Strandvik B, Ellin A, Wiman LG (1986) Increased mole fraction of arachidonic aeid in bronchial phospholipids in patients with cystic fibrosis. Scand J Clin Lab Invest 46:511–518
Gradon L, Podgorski A, Sosnowski T (1996) Experimental and theoretical inverstigations of transport properties of DPPC monolayer. J Aerosol Med 9:357–367
Griese M (1999) Pulmonary surfactant in health and lung diseases: State of the art. Eur Respir J 13:1455–1476
Griese M, Birrer P, Demirsoy A (1997a) Pulmonary surfactant in cystic fibrosis. Eur Respir J 10:1983–1988
Griese M, Butler P, Teller J, Reinhardt D (1997b) Nebulization of a bovine surfactant in cystic fibrosis: a pilot study. Eur Respir J 10:1989–1997
Griese M, Duroux A, Schams A, Lenz AG, Kleinasser N (1997c) Tracheobronchial surface active material in cystic fibrosis. Eur J Med Res 2:114–120
Heilmann P, Ferron G, Fuerst G, Moellenstadt S, Schumann G, Kreyling WG (1992) Effect of surfactant on airway mucociliary clearance function. Eur Respir J 5 (Suppl 15): 387s
Hull J, South M, Phelan P, Grimwood K (1997) Surfactant composition in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 156:161–165
Kurashima K, Fujimura M, Tsujiura M, Matsuda T (1997) Effect of surfactant inhalation on allergic bronchoconstriction in guinea pigs. Clin Exp Allergy 27:337–342
LeVine AM, Kurak K, Bruno MD, Stark J, Whitsett JA, Korfhagen TR (1998) Surfactant protein-A-deficient mice are susceptible to pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 19:700–708
Liu M, Wang L, Li E, Enhorning G (1991) Pulmonary Surfactant will secure free airflow through a narrow tube. J Appl Physiol 71:742–748
Liu M, Wang L, Li E, Enhorning G (1996) Pulmonary Surfactant given prophylactically alleviates an asthma attack in guinea-pigs. Clin Exp Allergy 26:270–275
Macklem PT, Proctor DF, Hogg JC (1970) The stability of peripheral airways. Respir Physiol 8:191–203
Nicholov R, Khoury A, Bruce A, DiCosmo F (1993) Interaction of ciprofloxacin loaded liposomes with pseudomonas aeruginosa cells. Cells Materials 3:321–326
Outzen KE, Svane-Knudsen V (1993) Effect of surface-active substance on nasal mucociliary clearance time: A comparison of saccharin clearance time before and after the use of surface-active substance. Rhinology 31: 155–157
Postle AD, Mander A, Reid KM, Wang JY, Wright S, Moustaki M, Warner J (1999) Deficient hydrophilic lung surfactant proteins A und D with normal surfactant phospholipid molecular spiecies in cystic fibrosis. Am J Respir Cell Mol Biol 20:90–98
Rubin BK, Ramirez O, King M (1992) Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy. Chest 101:1080–1085
Rudnik J, Hanicka M, Pawelek J, Zebrak J, Majewska-Zalewska H, Sowinska E (1983) Pulmonary surfactant contents in bronchial secretion in children with chronic respiratory diseases estimated by physico-chemical methods. Z Erkrank Atemw 160:44–47
Sahu S, Lynn WS (1977) Lipid composition of airways secretion from patients with asthma and patients with cystic fibrosis. Am Rev Respir Dis 115:233–239
De Sanctis GT, Tomkiewicz RP, Rubin BK, Schürch S, King M (1994) Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 7: 1616–1621
Van ‘t Veen A, Mouton J, Gommers D, Kluytmans J, Dekkers P, Lachmann B (1995) Influence of pulmonary surfactant on in vitro bactericidal activities if amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother 1995:329–333
Vos GD, Rijtema MN, Blanco CE (1996) Treatment of respiratory failure due to respiratory syncytial virus pneumonia with natural surfactant. Pediatr Pulmonol 22:412–415
Wright JR (1997) Immunomodulatory functions of Surfactant. Physiol Rev 77:931–961
Liteatur zu 4.5
Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD (1995) Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 310:1571–1572
Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R (1995) The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 20:63–70
Berger M (1991) Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy 9:119–142
Birrer P, McElvaney NG, Rüdeberg A, Wirz Sommer C, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150:207–213
Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF, Dearborn DG (1985) Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 132:529–535
Döring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G (1995) Cleavage of lymphocyte surface antigens CD2, CD4 and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 154:4842–4850
Goldstein W, Doering G (1986) Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 134: 49–56
Griese M, Schredl M, Hochstrasser K, Gebhard W (1997) Cellular association of antiproteases in lavages from ventilated preterm human neonates. Am J Respir Crit Care Med 155:2064–2071
Griese M, V Bredow C, Birrer P, Obermaier G (1999) Degradation of surfactant protein A and other BAL proteins in patients with cystic fibrosis. Netherl J Med 54:187, S71
Heinzel-Wieland R, Steffens GJ, Flohe L (1990) Inhibitory characteristics and oxidation resistance of site-specific variants of recombinant human antileukoproteinase. Biomed Biochim Acta 50:677–681
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151: 1075–1082
Konstan MW, Hilliard KA, Norvell TM, Berger M (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150:448–454
Konstan MW, Berger M (1997) Current understandig of the inflammatory process in cystic fibrosis: Onset and etiology. Pediatr Pulmonol 24:137–142
McElvaney N, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG (1991) Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 337:392–394
Nakamura H, Yoshimura K, McElvaney NG, Crystal RG (1992) Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 89:1478–1484
O’Connor CM, Gaffney K, Keane J, Southey A, Byrne N, O’Mahoney S, Fitzgerald MX (1993) α1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis 148:1665–1670
O’Connor CM, Fitzgerald MX (1994) Matrix metalloproteases and lung disease. Thorax 49:602–609
Rees DD, Roger RA, Cooley J, Mandle RJ, Kenney DM, Remold-O’Donnell E (1999) Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 20:69–78
Richman-Eisenstat JB, Jorens PG, Hebert CA, Ueki I, Nadel JA (1993) Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 264 (4 Pt 1):L413–L418
Schalkwijk J, Wiedow O, Hirose S (1999) The trappin gene family: Proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulfide-core. Biochem J 340:569–577
Schuster A, Ueki I, Nadel JA (1992) Neutrophil elastase stimulates tracheal submucosal gland secretion that is inhibited by ICI 200,355. Am J Physiol 262: L86–L91
Schuster A, Fahy JV, Ueki I, Nadel JA (1995) Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors. Eur Respir J 8:10–14
Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH (1990) Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J ClinInvest 85:682–689
Tizzano EF, Buchwald M (1992) Cystic fibrosis: Beyond the gene to therapy. J Pediatr 120:337–349
Tosi MF, Zakem H, Berger M (1990) Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 86:300–308
Tournier JM, Jacquot J, Puchelle E, Bieth JG (1985) Evidence that Pseudomonas elastase does not inactivate the bronchial inhibitor in the presence of leukocyte elastase. Am Rev Respir Dis 132:524–528
Travis J, Fritz H (1991) Potential problems in designing elastase inhibitors for therapy. Am Rev Respir Dis 143: 1412–1415
Vergnolle N, Hollenberg MD, Wallace JL (1999) Pro- and antiinflammatory actions of thrombin: a distinct role for proteinase activated receptor-1 (PARI). Br J Pharmacol 126:1262–1269
Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, Crystal RG (1991) Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 87:482–488
Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM (1999) Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 276:L835–L843
Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbaum P, Ueki I, Canteloup S, Lenoir G, Descamps-Latscha B, Nadel JA (1999) Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 20:729–736
Liteatur zu 4.6
Brown RK, Wyatt H, Price JF, Kelly FJ (1996) Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J 9 (2): 334–339
Cantin AM, Begin R (1991) Glutathione and inflammatory disorders of the lung. Lung 169:123–138
Cantin AM, North SL, Hubbard RC, Crystal RG (1987) Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 63:152–157
Crystal RG (1991) Oxidants and respiratory tract epithelial injury: pathogenesis and strategies for therapeutic intervention. Am J Med 91 (3c):39s–44s
Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol 257: L163–L173
Doelman CJA, Bast A (1990) Oxygen radicals in lung pathology. Free Radic Biol Med 9:381–400
Döring G (1996) Mechanisms of airway inflammation in cystic fibrosis. Pediatr Allergy Immunol 7 (Suppl 9):63–66
Heffner JE, Repine JE (1989) Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 140:531–554
Henson PM, Johnston RP (1987) Tissue injury in inflammation: oxidants, proteinases, and cationic proteins. J Clin Invest 79:669–674
Van Klaveren RJ, Demedts M, Nemery B (1997) Cellular glutathione turnover in vitro, with emphasis on type II pneumocytes. Eur Respir J 10:1392–1400
Klebanoff SJ (1992) Oxygen metabolites from phagocytes. In: Gallin JI, Goldstein IM, Snyderman R (eds) Inflammation: Basic principles and clinical correlates. Raven Press, New York, pp 541–588
Lands LC, Grey V, Smountas AA, Kramer VG, McKenna D (1999) Lymphocyte glutathione levels in children with cystic fibrosis. Chest 116 (l):201–205
Linsdell P, Hanrahan JW (1998) Glutathione permeability of CFTR. Am J Physiol 275 (Cell Physiol 44): C323–C326
Meyer KC, Zimmerman J (1993) Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 121:654–661
Range SP, Dunster C, Knox AJ, Kelly FJ (1999) Treatment of pulmonary exaeerbations of cystic fibrosis leads to improved antioxidant status. Eur Respir J 13 (3): 560–564
Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG (1993) Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 75 (6):2419–2424
Roum JH, Borok Z, McElvany NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG (1999) Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 87 (1): 438–443
Swaim MW, Pizzo SV (1988) Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. JleukocBiol 43: 365–379
Van der Vliet A, Eiserich JP, Marelich GP, Halliwell B, Cross CE (1997) Oxidative stress in cystic fibrosis: does it occur and does it matter ? Adv Pharmacol 38:491–513
Weiss SJ (1989) Tissue destruetion by neutrophils. N Engl J Med 320:365–376
Winklhofer-Roob BM (1994) Oxygen free radicals and antioxidants in cystic fibrosis: the coneept of an oxidant-antioxidant imbalance. Acta Paediatri 395 (Suppl):49–57
Winklhofer-Roob BM, Schlegel-Haueter SE, Khoschsorur G, van’t-Hof MA, Suter S, Shmerling DH (1996) Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation. Pediatr Res (1): 130–134
Winklhofer-Roob BM, Ellemunter H, Fruhwirth M, Schlegel-Haueter SE, Khoschsorur G, van’t Hof MA, Shmerling DH (1997) Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation. Am J Clin Nutr 65 (6): 1858–1866
Winklhofer-Roob BM, Tiran B, Tuchschmid PE, van’t Hof MA, Shmerling DH (1998) Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxi-dase activities and plasma selenium concentrations in cystic fibrosis. Free Radic Biol Med 25 (2): 242–249
Worlitzsch D, Herberth G, Ulrich M, Döring G (1998) Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis. Eur Respir J 11:377–383
Liteatur zu 4.7
Abrahamson IS, Coffman RL (1995) Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection. J Immunol 155:3955–3963
Abughali N, Berger M, Tosi MF (1994) Deficient total cell content of CR3 (CD 11b) in neonatal neutrophils. Blood 83:1086–1092
Anderson TR, Montie TC, Murphy MD, McCarthy VP (1989) Pseudomonas aeruginosa flagellar antibodies in patients with cystic fibrosis. J Clin Microbiol 27: 2789–2793
Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JR, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD (1997) Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 156:1197–1204
Aronoff SC, Quinn Jr FJ, Stern RC (1991) Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatr Pulmonol 11:289–293
Aruoma OI, Halliwell B, Hoey BM, Butler J (1988) The an-tioxidant action of taurine, hypotaurine and their meta-bolic precursors. Biochem J 256:251–255
Banda MJ, Rice AG, Griffin GL, Senior RM (1988) Alpha I-proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. J Biol Chem 263:4481–4484
Barasch J, Kiss B, Prince A, Saiman L, Gruenert D, Al-Awqati Q (1991) Defective acidification of intracellular organelles in cystic fibrosis. Nature 352:70–73
Barnes PJ, Liew FY (1995) Nitric oxide and asthmatic inflammation. Immunol Today 16:128–130
Baumstark JS, Lee CT, Luby RJ (1977) Rapid inactivation of alpha1-protease inhibitor (alpha1-antitrypsin) by elastase. Biochim Biophys Acta 482:400–411
Behr J, Maier K, Krombach F, Adelmann-Grill BC (1991) Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis. Am Rev Respir Dis 144: 146–150
Berger M (1990) Complement deficiency and neutrophil dysfunction as risk factors for bacterial infection in newborns and the role of granulocyte transfusion in therapy. Rev Infect Dis 12:S401–S409
Berger M, Norvell TM, Tosi MF, Emancipator SN, Konstan MW, Schreiber JR (1994) Tissue-specific Fc gamma and complement receptor expression by alveolar macrophages determines relative importance of IgG and complement in promoting phagocytosis of Pseudomonas aeruginosa. Pediatr Res 35:68–77
Berger M, Sorensen RU, Tosi MF, Dearborn DG, Döring G (1989) Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 84:1302–1313
Biggar WD, Holmes B, Good RA (1971) Opsonic defect in patients with cystic fibrosis of the pancreas. Proc Natl Acad Sci USA 68:1716–1719
Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 150:207–213
Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M (1995) Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10,which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 13: 257–261
Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152:2111–2118
Boucher RC, Stutts MJ, Knowles MR, Cantley L, Gatzy JT (1986) Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 78:1245–1252
Boucher JC, Yu H, Mudd MH, Deretic V (1997) Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 65:3838–3846
Breuer R, Christensen TG, Niles RM, Stone PJ, Snider GL (1989) Human neutrophil elastase causes glycoconjugate release from the epithelial cell surface of hamster trachea in organ eulture. Am Rev Respir Dis 139:779–782
Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski Jr JF, Dearborn DG (1985) Biochemical and pathological evidence for proteolytic destruetion of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 132: 529–535
Cabral DA, Loh BA, Speert DP (1987) Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages. Pediatr Res 22:429–431
Christensen TG, Breuer R, Hornstra LJ, Lucey EC, Stone PJ, Snider GL (1987) An ultrastructural study of the response of hamster bronchial epithelium to human neutrophil elastase. Exp Lung Res 13:279–297
Cowan RG, Winnie GB (1993) Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil Chemotaxis, and phagocytosis. J Clin Immunol 13:359–370
Cromwell O, Walport MJ, Morris HR, Taylor GW, Hodson HR, Barten J, Kay AB (1981) Identification of leukotrienes D and B in sputum from cystic fibrosis patients. Lancet 1: 164–165
Cross CE, Halliwell B, Allen A (1984) Antioxidant protection: a function of tracheobronchial and gastrointestinal mucus. Lancet 1:1328
Dai Y, Dean TP, Church MK, Warner JO, Shute JK (1994) Desensitisation of neutrophil responses by systemic interleukin 8 in cystic fibrosis. Thorax 49:867–871
Dasgupta M, Lam J, Dbring G, Harley F, Zuberbuhler P, Lam K, Reichert A, Costerton WJ, Dossetor JB (1987) Prognostic implications of circulating immune complexes and Pseudomonas aeruginosa-speeifie antibodies in cystic fibrosis. J Clin Lab Immunol 23:25–30
de Bentzmann S, Roger P, Dupuit F, Bajolet-Laudinat O, Fuchey C, Plotkowski MC, Puchelle E (1996) Asialo GM1 is a reeeptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect Immun 64:1582–1588
de Bentzmann S, Roger P, Puchelle E (1996) Pseudomonas aeruginosa adherence to remodelling respiratory epithelium. Eur Respir J 9:2145–2150
Desrochers PE, Jeffry JJ, Weiß SJ (1991) Interstitial collagenase (matrixmetalloproteinase-1) expresses serpinase activity. J Clin Invest 87:2258–2265
DiMango E, Zar HJ, Bryan R, Prince A (1995) Diverse Pseudomonas aeruginosa gene produets stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 96:2204–2210
DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A (1998) Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 101:2598–2605
Dong YJ, Chao AC, Kouyama K, Hsu YP, Bocian RC, Moss RB, Gardner P (1995) Activation of CFTR chloride current by nitric oxide in human T lymphocytes. EMBO J 14: 2700–2707
Döring G, Høiby N (1983) Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun 42:197–201
Döring G, Goldstein W, Rüll W, Schiøtz PO, Høiby N, Botzenhart K (1985) Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun 49:557–462
Döring G, Buhl V, Høiby N, Schiøtz PO, Botzenhart K (1984) Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from the sputum of cystic fibrosis patients. Acta Pathol Microbiol [C] 92: 307–311
Döring G, Obernesser HJ, Botzenhart K, Flehmig B, Høiby N, Hofmann A (1983) Proteases of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis 147:744–750
Döring G (1989) Polymorphonuclear leukocyte elastase: its effects on the pathogenesis of Pseudomonas aeruginosa infection in cystic fibrosis. Antibiot Chemother 42: 169–176
Döring G, Müller E (1989) Different sensitivity of Pseudomonas aeruginosa exotoxin A and diphtheria toxin to enzymes from polymorphonuclear leukocytes. Microb Pathog 6:287–295
Döring G, Dauner HM (1988) Clearance of Pseudomonas aeruginosa in different rat lung infection modes. Am Rev Respir Dis 138:1249–1253
Döring G, Krogh-Johansen H, Weidinger S, Høiby N (1994) Allotypes of alpha1-antitrypsin in cystic fibrosis patients homozygous and heterozygous for delta 508. Pediatr Pulmonol 18:3–7
Döring G, Knight R, Bellon G (1994) Immunology of cystic fibrosis. In: Hodson ME, Geddes D (eds) Cystic fibrosis. Arnold, London, pp 109–40
Döring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G (1995) Cleavage of lymphocyte surface antigens CD2, CD4 and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 154:4842–4850
Döring G (1994) The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 150: S114–S117
Döring G, Goldstein W, Botzenhart K, Kharazmi A, Schiøtz PO, Høiby N, Dasgupta M (1986) Elastase from polymorphonuclear leukocytes — a regulatory enzyme in immune complex disease. Clin Exp Immunol 64:597–605
Dal Nogare AR, Toews GB, Pierce AK (1987) Increased salivary elastase precedes gram-negative bacillary colonization in postoperative patients. Am Rev Respir Dis 135: 671–675
Dotsch J, Demirakca S, Terbrack HG, Huls G, Rascher W, Kuhl PG (1996) Airway nitric oxide in asthmatic children and patients with cystic fibrosis. Eur Respir J 12: 2537–2540
Eichler 1, Joris L, Hsu YP, Van Wye J, Bram R, Moss R (1989) Nonopsonic antibodies in cystic fibrosis. J Clin Invest 84:1294–1304
Ericsson-Hollsing A, Granström M, Vasil ML, Wretlind B, Strandvik B (1987) Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol 25:1868–1874
Fick RB, Naegel GP, Squier SU, Wood RE, Gee BL, Reynolds HY (1984) Proteins of the cystic fibrosis respiratory tract. J Clin Invest 74:236–248
Fick Jr RB, Robbins RA, Squier SU, Schoderbek WE, Ruß WD (1986) Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res 20:1258–1268
Vane JR, Botting RM (1992) The role of chemical mediators released by the endothelium in the control of the cardiovascular system. Int J Tissue React 14:55–64
Fomsgaard A, Svenson M, Bendtzen K (1989) Auto-anti-bodies to tumor necrosis factor a in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol 30:219–223
Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM (1997) Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553–560
Goldstein W, Döring G (1986) Lysosomal enzymes and proteinase inhibitors in the sputum of patients with cystic fibrosis. Am Rev Respir Dis 134:49–56
Grasemann H, Michler E, Wallot M, Ratjen F (1997) Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 24: 173–177
Greenberg DP, Stutman HR (1990) Infection and immunity to Staphylococcus aureus and Haemophilus influenzae. In: Moss RB (ed) Cystic fibrosis. Infection, immuno-phathology and host response. Humana Press, Clifton, New Jersey, pp 75–86
Halliwell B, Gutteridge JM (1986) Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 246:501–514
Hamilton RG (1987) Human IgG subclass measurements in the clinical laboratory. Clin Chem 33:1707–1725
Hancock REW, Movat ECA, Speert DP (1984) Quantitaten and identification of antibodies to outer membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis. J Infect Dis 149:220–226
Hannah S, Mecklenburgh K, Rahman I, Bellingan GJ, Greening A, Haslett C, Chilvers ER (1995). Hypoxia prolongs neutrophil survival in vitro. FEBS Lett 372:233–237
Høiby N, Olling S (1977) Pseudomonas aeruginosa infection in cystic fibrosis. Acta Pathol Microbiol Scand [C] 85: 107–114
Hornick DB, Fick Jr RB (1990) The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. J Clin Invest 86:1285–1292
Imundo L, Barasch J, Prince A, Al-Awqati Q (1995) Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 92:3019–30233
Johansen HK, Norgaard A, Andersen LP, Jensen P, Nielsen H, Høiby N (1995) Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori. Clin Diagn Lab Immunol 2:149–155
Johnson D, Travis J (1979) The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem 254: 4022
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151: 1075–1082
Karnosinska B, Radomski MW, Duszyk M, Radomski A, Man SIT (1997) Nitric oxide activates chloride currents in human lung epithelial cells. Am J Physiol 272: L1098–L1104
Knutsen AP, Slavin RG (1990) Allergie bronchopulmonary aspergillosis in patients with cystic fibrosis. In: Moss RB (ed) Cystic fibrosis. Infection, immunopathology and host response. Humana Press, Clifton, New Jersey, pp 103–118
Koller DY, Urbanek R, Gotz M (1995) Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. Am J Respir Crit Care Med 152:629–633
Konstan MW, Hilliard KA, Norvell TM, Berger M (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest on-going infection and inflammation. Am J Respir Crit Care Med 150:448–454
Krivan HC, Roberts DD, Ginsburg V (1988) Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence Gal NAcI-4Gal found in some glycolipids. Proc Natl Acad Sci USA 85:6157–6161
Kronberg G, Fomsgaard A, Galanos C, Freudenberg MA, Høiby N (1992) Antibody responses to lipid A, core and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients. J Clin Microbiol 330:1848–1855
Kronborg G (1995) Lipopolysaccharide (LPS), LPS-im-mune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS Suppl 50:1–30
Kubiet M, Ramphai R (1995) Adhesion of nontypeable Haemophilus influenzae from blood and sputum to human tracheobronchial mucins and lactoferrin. Infect Immun 63:899–902
Lacy DE, Smith AW, Lambert PA, Peckham D, Stableforth DE, Smith EG, Desai M, Weller PH, Brown MR (1997) Serum IgG response to an outer membrane porin protein of Burkholderia cepacia in patients with cystic fibrosis. FEMS Immunol Med Microbiol 17:87–94
Langley SC, Brown RK, Kelly FJ (1993) Reduced free-radical-trapping capacity and altered plasma antioxidant status in cystic fibrosis. Pediatr Res 33:247–250
Learn DB, Brestel EP, Seethararna S (1987) Hypochlorite seavenging by Pseudomonas aeruginosa alginate. Infect Immun 55:1813–1818
Lloyd-Still JD (1983) Pulmonary manifestations. In: Lloyd-Still JD (ed) Textbook of cystic fibrosis. John Wright, Boston, pp 165–198
Lo SK, Janakidevi K, Lai L, Malik ABI (1993) Hydrogen peroxide-induced increase in endothelial adhesiveness is dependent on ICAM-1 activation. Am J Physiol 264: L406–L412
Lundberg JO, Nordvall SL, Weitzberg E, Kollberg H, Alving K (1996) Exhaled nitric oxide in paediatric asthma and cystic fibrosis. Arch Dis Child 75:323–326
MacCartney HW, Tschesche H (1980). Latent collagenase from human polymorphonuclear leueocytes and activation to collagenase by removal of a inhibitor. FEBS Lett 119:327–332
Mahadeva R, Stewart S, Bilton D, Lomas DA (1998) Alpha-1-antitrypsin deficiency alleles and severe cystic fibrosis lung disease. Thorax 53:1022–1024
Mathee K, Coifu O, Sternberg C, Lindum PW, Campbell JIA, Jensen P, Johnsen AH, Givskov M, Ohman DE, Molin S, Hoiby N, Kharazmi A (1999) Muocid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145:1349–1357
Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 5: 1005–1015
Matthews WJ Jr, Williams M, Oliphant B, Geha R, Colton HR (1980) Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med 302:245–249
McKenney D, Tibbetts KL, Wang Y, Murthy V, Ulrich M, Döring G, Lee JC, Goldmann DA, Pier GB (1999) Broadly-protective vaccine for Staphylococcus aureus based on an in vivo expressed antigen. Science 284:1523–1527
Meng Q-H, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, Gruenert DC, Hodson ME, Yacoub MH, Polak JM (1998) Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of suseeptibility to infection in cystic fibrosis. J Pathol 184:323–331
Meyer KC, Sharma A, Rosenthal NS, Peterson K, Brennan L (1997) Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 156:1536–1540
Meyer KC, Zimmerman J (1993) Neutrophil mediators, Pseudomonas, and pulmonary dysfunetion in cystic fibrosis. J Lab Clin Med 121:654–661
Miller EJ, Nagao S, Carr FK, Noble JM, Cohen AB (1996) Interleukin-8 (IL-8) is a major neutrophil chemotaxin from human alveolar macrophages stimulated with staphylococcal enterotoxin A. Inflamm Res 45:386–392
Mizgerd JP, Kobzik L, Warner AE, Brain JD (1995) Effects of sodium concentration on human neutrophil bactericidal functions. Am J Physiol 269: L388–L393
Moldawer LL, Lowry SF (1988) Cachectin: its impact on metabolism and nutritional status. Annu Rev Nutr 8: 585–609
Moncada S, Higgs EA (1991) Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 21:361–374
Moser C, Johansen HK, Song Z, Hougen HP, Rygaard J, Høiby N (1997) Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Thl responding C3H/HeN mice. APMIS 105: 838–842
Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, Gardner P (1996) Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conduetance regulator (CFTR). Clin Exp Immunol 106:374–388
Moss RB, Hsu YP, Lewiston NJ, Curd JG, Milgrom H, Hart S, Dyer B, Larrick JW (1986) Association of specific immune complexes, complement activation and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am Rev Respir Dis 133:648–652
Nakamura H, Yoshimura K, McElvaney, Crystal RG (1992) Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 89:1478–1484
Nicolai T, Arleth S, Spaeth A, Bertele-Harms RM, Harms HK (1990) Correlation of IgE antibody titer to Aspergillus fumigatus with decreased lung function in cystic fibrosis. Pediatr Pulmonol 8:12–15
Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW (1997) Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 175:638–647
O’Connor CM, FitzGerald MX (1994) Matrix metalloproteases and lung disease. Thorax 49:602–609
Palfreyman RW, Watson ML, Eden C, Smith AW (1997) In-duction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia produets. Infect Immun 65:617–622
Pedersen SS, Espersen F, Hoiby N, Jensen T (1990) Immunoglobulin A and Immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol 28:747–755
Pedersen SS, Espersen F, Høiby N (1987) Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol 25:1830–1836
Perlmutter DH, Joslin G, Nelson P, Schasteen C, Adams SP, Fallon RJ (1990) Endocytosis and degradation of alphar antitrypsin-protease complexes is mediated by the ser-pin-enzyme complex (SEC) receptor. J Biol Chem 265: 16713–16716
Pier GB, Saunders JM, Arnes P, Edwards MS, Auerbach HS, Goldfarb J, Speert DP, Hurwitch S (1987) Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med 317:793–798
Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB (1996) Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271:64–67
Pier GB, Grout M, Zaidi TS (1997) Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 94:12088–1209–33
Plotkowski MC, Chevillard M, Pierrot D, Altemayer D, Puchelle E (1992) Epithelial respiratory cells from cystic fibrosis patients do not possess specific Pseudomonas aeruginosa-adhesive properties. J Med Microbiol 36: 104–111
Plotkowski MC, Beck G, Tournier JM, Bernardo-Filho M, Marques EA, Puchelle E (1989) Adherence of Pseudomonas aeruginosa to respiratory epithelium and the effect of leucocyte elastase. J Med Microbiol 30:285–293
Portal BC, Richard MJ, Faure HS, Hadjian AJ, Favier AE (1995). Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr 61:843–847
Power C, O’Connor CM, Macfarlane D, O’Mahoney S, Gaffney K, Hayes J, Fitzgerald MX (1994) Neutrophil collagenase in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 150:818–822
Pressler T, Jensen ET, Espersen F, Pedersen SS, Hoiby N (1995) High levels of complement-activation capacity in sera from patients with cystic fibrosis correlate with high levels of IgG3 antibodies to Pseudomonas aeruginosa antigens and poor lung function. Pediatr Pulmonol 20: 71–77
Regelmann WE, Siefferman CM, Herron JM, Elliott GR, Clawson CC, Gray BH (1995) Sputum peroxidase activity correlates with the severity of lung, disease in cystic fibrosis. Pediatr Pulmonol 19:1–9
Rourn JH, Buhl R, McElvaney NG, Borok Z, Crystal RG (1993) Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 75:2419–2424
Sajjan SU, Corey M, Karmali MA, Forstner JF (1992) Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest 89:648–656
Salva PS, Doyle NA, Graham L, Eigen H, Doerschuk CM (1996) TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 21:11–19
Scharfman A, Kroczynski H, Carnoy C, Van Brussel E, Lamblin G, Ramphai R, Roussel P (1996) Adhesion of Pseudomonas aeruginosa to respiratory mucins and expression of mucin-binding proteins are increased by limiting iron during growth. Infect Immun 64:5417–5420
Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-l. EMBO J 10:2247–2258
Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA (1992) Dithiocarbarnates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 175: 1181–1194
Schuster A, Csemok E, Johnston TW, Groß W (1997) Proteinase-3 in cystic fibrosis airways. Am J Respir Crit Care Medl 55:A49
Schwab UE, Wold AE, Carson JL, Leigh MW, Cheng PW, Gilligan PH, Boat TF (1993) Increased adherence of Staphylococcus aureus from cystic fibrosis lungs to airway epithelial cells. Am Rev Respir Dis 148:365–369
Seksek 0, Biwersi J, Verkman AS (1996) Evidence against defective trans-Golgi acidification in cystic fibrosis. J Biol Chem 271:15542–15548
Shak S, Goldstein IM (1984) Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. J Biol Chem 259: 10181–10187
Shapira E, Wilson GB (1984) Immunological aspects of cystic fibrosis. CRC Press, Boca Raton, Florida
Simpson JA, Smith SE, Dean RT (1989) Scavening by alginate of free radicals released by macrophages. Free Radic Biol Med 6:347–353
Skov M, Poulsen LK, Koch C (1999) Increased antigen-specifie Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol 27:74–79
Smith JJ, Travis SM, Greenberg EP, Welsh MJ (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229–233
Smith JJ, Travis SM, Greenberg EP, Welsh MJ (1996) Erratum. Cell 87:335
Sommerhof CP, Nadel JA, Basbaum CB, Caughey GH (1990) Neutrophil elastase and cathepsin G stimulate secretion from eultured bovine airway gland serous cells. J Clin Invest 85:682–689
Sordelli DO, Djafari M, Garcia VE, Fontan PA, Döring G (1992) Age-dependent pulmonary clearance of Pseudomonas aeruginosa in a mouse model: diminished migration of polymorphonuclear leukocytes to N-formyl-methionyl-leucylphenylalanine. Infect Immun 60: 1724–1727
Sorensen RU, Sern RC, Chase PA, Polmar SH (1981) Changes in lymphocyte reactivity to Pseudomonas aeruginosa in hospitalized cystic fibrosis patients. Am Rev Respir Dis 123:37–41
Steinkamp G, Drommer A, von der Hardt H (1993) Resting energy expenditure before and after treatment for Pseudomonas aeruginosa infection in patients with cystic fibrosis. Am J Clin Nutr 57:685
Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL (1995) Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 152:157–162
Suter S, Schaad UB, Roux L, Nydegger UE, Waldvogel FA (1984) Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis 149:523–531
Swaim MW, Pizzo SV (1988) Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. J Leukoc Biol 43:365–379
Teramoto S, Matsuse T, Ouchi Y (1997) Increased production of TNF-alpha may play a role in osteoporosis in cystic fibrosis patients. Chest 112:574
Thansekaraan V, Wiseman MS, Rayner RJ, Hiller EJ, Shale DJ (1989) Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis. Arch Dis Child 64:1599–1603
Thomassen MJ, Boxerbaum B, Demko CA, Kuchenbrod PJ, Dearborn DG, Wood RE (1979) Inhibitory effect of cystic fibrosis serum on Pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr Res 13: 1085–1088
Tosi MF, Zakem-Cloud H, Demko CA, Schreiber JR, Stern RC, Konstan MW, Berger M (1995) Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis 172: 453–461
Tosi MF, Zakem H, Berger M (1990) Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CRI on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 86:300–308
Tsujimoto M, Yokota S, Vilcek J, Weissmann G (1986) Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun 137:1094–1100
Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Munker G, Döring G (1998) Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture model of S. aureus adherence. Am J Respir Crit Care Med 18:1–9
Weiß SJ, Peppin GJ (1986) Collagenolytic metalloenzymes of the human neutrophil. Characteristics, regulation and potential function in vivo. Biochem Pharmacol 35:3189–3197
Winnie GB, Cowan RG (1991) Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlation between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 10:92–100
Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT, Descamps-Latscha B (1995) Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am J Respir Crit Care Med 152:1910–1916
Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbaum P, Ueki I, Canteloup S, Lenoir G, Descamps-Latscha B, Nadel JA (1999) Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 20:729–736
Worlitzsch D, Herberth G, Ulrich M, Döring G (1998) Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis. Eur Respir J 11:377–383
Zahm JM, Gaillard D, Dupuit F, Hinnrasky J, Porteous D, Dorin JR, Puchelle E (1997) Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice. Am J Physiol 272: C853–C859
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
App, E.M. et al. (2001). Abwehrsysteme. In: Reinhardt, D., Götz, M., Kraemer, R., Schöni, M.H. (eds) Cystische Fibrose. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56796-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-56796-4_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63172-6
Online ISBN: 978-3-642-56796-4
eBook Packages: Springer Book Archive